Sichuan Biokin Secures Four Phase II Approvals for BL-B01D1 in Combination Therapies
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has secured four...
Hansoh Pharmaceutical Gains Clinical Approval for KRAS G12D Targeted Drug HS-10529
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced that it has received clinical...
AccurEdit Therapeutics Reports Positive 24-Week Data for ART002 in HeFH Patients
Suzhou-based gene editing specialist AccurEdit Therapeutics has announced the completion of a 24-week follow-up for...
Cyprumed Signs Non-Exclusive License Agreement with MSD for Oral Peptide Delivery Tech
Germany-based Cyprumed GmbH has entered into a non-exclusive license and option agreement with Merck, Sharp...
US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security
The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the...
Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q1 2025 revenues of USD...
BMS Faces Phase III Setback for Camzyos in Non-Obstructive HCM Study
US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has reported a setback in the Phase...
Beijing Wantai Launches Phase III Trial for 9-Valent HPV Vaccine in Chinese Males
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has initiated a Phase III...
Jiangsu Nhwa Initiates Phase I Trial for NH280105, an Oral Lp-PLA₂ Inhibitor for Alzheimer’s Disease
China-based Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262) has announced the initiation of a Phase...
Hengrui Pharmaceuticals Gains NMPA Clearance for Phase II Study of HRS-7058 in Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced clearance from the National Medical...
Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its...
Roche’s Columvi Approved by EC for Relapsed DLBCL Treatment in Europe
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that it has received marketing...
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-1819 in Allergic Rhinitis Study
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received approval...
CSPC Pharmaceutical Gains FDA Approval for SYS6041 ADC in Advanced Solid Tumors
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...
Boehringer Ingelheim Partners with Cue Biopharma to Advance CUE-501 for Autoimmune Diseases
Germany’s Boehringer Ingelheim (BI) has entered into a strategic agreement with US-based Cue Biopharma, Inc....
Peijia Medical’s TaurusTrio TAV System Accepted for NMPA Review in China
China-based Peijia Medical Ltd (HKG: 9996) has announced that the National Medical Products Administration (NMPA)...
HighTide Therapeutics’ HTD1801 Shows Positive Phase III Results in Type 2 Diabetes Treatment
China-based HighTide Therapeutics Inc. (HKG: 2511) has announced positive results from two Phase III clinical...
Zhuhai Beihai Biotech Gains NMPA Clinical Clearance for Innovative Peptide-Drug Conjugate BH259
China-based Zhuhai Beihai Biotech Co., Ltd. has announced that it has received clinical trial clearance...
Novlead Biotech Secures Series C Financing to Expand NO Inhalation Therapy Device Production
Novlead Biotech, a Nanjing-based specialist in nitric oxide (NO) gas detection and treatment, has secured...
Chromatin Bioscience Collaborates with Astellas Pharma to Design Cell-Selective Synthetic Promoters
UK-headquartered Chromatin Bioscience has entered into a collaboration with Japan-based Astellas Pharma Inc. (TYO: 4503)...